Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $2.66, but opened at $2.83. Sana Biotechnology shares last traded at $2.75, with a volume of 539,172 shares changing hands.
Analysts Set New Price Targets
A number of research firms have recently issued reports on SANA. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research note on Wednesday, January 8th. Jefferies Financial Group initiated coverage on Sana Biotechnology in a report on Friday. They issued a "buy" rating and a $7.00 price target on the stock. Finally, HC Wainwright upped their price objective on Sana Biotechnology from $8.00 to $11.00 and gave the stock a "buy" rating in a research note on Wednesday, January 8th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Sana Biotechnology presently has an average rating of "Moderate Buy" and a consensus target price of $12.25.
Read Our Latest Research Report on SANA
Sana Biotechnology Stock Performance
The stock has a market cap of $654.18 million, a PE ratio of -2.09 and a beta of 1.63. The firm has a fifty day moving average price of $3.03 and a 200 day moving average price of $3.27.
Insider Buying and Selling at Sana Biotechnology
In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company's stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares in the company, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 31.10% of the stock is currently owned by company insiders.
Institutional Investors Weigh In On Sana Biotechnology
Large investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. lifted its position in Sana Biotechnology by 10.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company's stock worth $77,000 after acquiring an additional 4,554 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Sana Biotechnology by 17.9% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company's stock worth $146,000 after purchasing an additional 5,338 shares during the period. Teacher Retirement System of Texas boosted its position in Sana Biotechnology by 20.3% in the fourth quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company's stock valued at $60,000 after buying an additional 6,209 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company's stock worth $457,000 after buying an additional 6,613 shares during the period. Finally, Blue Trust Inc. raised its position in Sana Biotechnology by 51.0% during the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company's stock worth $32,000 after buying an additional 6,694 shares during the last quarter. 88.23% of the stock is owned by hedge funds and other institutional investors.
Sana Biotechnology Company Profile
(
Get Free Report)
Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.
Featured Stories
Before you consider Sana Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sana Biotechnology wasn't on the list.
While Sana Biotechnology currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
